Ovarian Cancer

Rucaparib Maintenance Extends Survival in Platinum-Sensitive Ovarian Cancer

Phoebe Starr

November 2017, Vol 7, No 11 - ESMO Highlights, Ovarian Cancer

Madrid, Spain—Maintenance therapy with the poly ADP-ribose polymerase (PARP) inhibitor rucaparib (Rubraca) after response to platinum-containing therapy significantly improved progression-free survival (PFS) by 11.2 months in patients with recurrent ovarian cancer compared with placebo, according to overall results of the ARIEL3 trial. The study was presented at the 2017 European Society for Medical Oncology (ESMO) Congress. [ Read More ]